Aclaris Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Aclaris Therapeutics Inc ACRS.OQ reported a quarterly adjusted loss of 13 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -15 cents. The mean expectation of eight analysts for the quarter was for a loss of 13 cents per share. Wall Street expected results to range from -16 cents to -12 cents per share.

• Revenue fell 35.8% to $1.78 million from a year ago; analysts expected $1.37 million.

• Aclaris Therapeutics Inc's reported EPS for the quarter was a loss of 13 cents​.

• The company reported a quarterly loss of $15.43 million.

• Aclaris Therapeutics Inc shares had risen by 9.2% this quarter and lost 37.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 8.4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Aclaris Therapeutics Inc is $7.00, about 77.9% above its last closing price of $1.55

This summary was machine generated from LSEG data August 7 at 04:40 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)